RxDoctor Payments Data

Micah Leleux, MD

Family Medicine · Lake Charles, LANPI 1063711943

Payments from drug & device makers

$8,225in general payments, 2019–2025

Across 503 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$889
  • Novo Nordisk$553
  • Pfizer$552
  • Lilly USA, LLC$547
  • Amgen$483
  • plus $3K from 45 others

What the payments were for

  • Food & beverage$8,16599%
  • Education$10%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,225 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$66,743
Medicare patients
277
Services billed
2,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide217$260,898
OzempicSemaglutide113$136,040
JardianceEmpagliflozin76$77,007
EliquisApixaban77$65,618
FarxigaDapagliflozin Propanediol65$63,018
XareltoRivaroxaban78$58,897
TrulicityDulaglutide29$54,080
LinzessLinaclotide50$37,856
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$19,573
Tresiba Flextouch U-100Insulin Degludec14$15,929
MyrbetriqMirabegron20$14,800
Spiriva RespimatTiotropium Bromide29$14,745
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,516
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$9,930
LantusInsulin Glargine,hum.Rec.Anlog11$7,151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$547$314,978246 claims
Novo NordiskOzempic$553$136,040113 claims
Boehringer IngelheimJardiance, Spiriva Respimat$155$91,753105 claims
PfizerEliquis$552$65,61877 claims
AstraZenecaFarxiga$889$63,01865 claims
Johnson & JohnsonXarelto$31$58,89778 claims
AbbVieLinzess, Fetzima, Synthroid$1,880$46,414109 claims
GSKTrelegy Ellipta$112$19,57325 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$199$17,66723 claims
Astellas Pharma US IncMyrbetriq$246$14,80020 claims
NovartisEntresto$105$5,28811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →